Table 1.

Audiometry findings, present regimen and length of aminoglycoside use in group I(n = 7) and II (n = 4) patients showing audiological evidence of hearing loss

Sr. No. (Group)	Length of treatment (Days)	Present regimen (Drugs)	PTA0	PTA2	PTA4	PTA6	PTA8	PTA10	PTAc
1 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
2 (I)	60	A, F, E, P, Py	N	HFL	HFL	HFL	FLAT	FLAT	FLAT
3 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
4 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	FLAT	FLAT
5 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
6 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
7 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
8 (II)	120	K, F, E, P, Py	N	N	N	HFL	FLAT	FLAT	FLAT
9 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
10 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	FLAT	FLAT
11 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL

A = amikacin, F = flouroquinolone, E = ethionamide, P = Para-amino salicylic acid, Py = Pyrazinamide, K = kanamycin, Days = days of aminoglycoside use in present regimen, PTA0 = baseline pure tone audiogram, PTA2 = pure tone audiogram after 2 months of aminoglycoside use, PTA4 = pure tone audiogram after 4 months of aminoglycoside use, PTA6 = pure tone audiogram after 6 months of aminoglycoside use, PTA8 = pure tone audiogram after 8 months of aminoglycoside use, PTA10 = pure tone audiogram after 10 months of aminoglycoside use, PTAc = pure tone audiogram after completion of therapy for MDR-TB, N = Normal, HFL = High frequency loss (hearing loss involving frequencies of 4000, 6000 and 8000 Hz), FLAT = Hearing loss involving frequencies in range of 250–3000 Hz along with involvement of 4000, 6000 and 8000 Hz (Criteria for hearing loss as defined in methods section).